Bli medlem
Bli medlem

Du är här

2015-04-20

Medigene AG: Clinical data of Medigene's dendritic cell (DC) vaccines presented at AACR conference

Medigene AG / Clinical data of Medigene's dendritic cell (DC) vaccines
presented at AACRconference . Processed and transmitted by NASDAQ OMX
Corporate Solutions.The issuer is solely responsible for the content of this
announcement.
Press Release
Martinsried/Munich, 20 April, 2015.
Medigene AG(MDG1, Frankfurt, Prime Standard) announces that early clinical
data of its dendritic cell (DC) vaccines were presented today at the American
Association for Cancer Research (AACR) Annual Meeting in Philadelphia, USA.
The clinical data were collected in an ongoing compassionate use
program[1]conducted at the Department of Cellular Therapy at the Oslo
University Hospital, Norway, under the responsibility of Prof. Gunnar
Kvalheim. The poster presentation titled "A new generation of dendritic cells
to improve cancer therapy shows prolonged progression free survival in
patients with solid tumors" provides data from patients with various types of
tumour which were included in this program.

In summary, one lung cancer patient, one prostate cancer patient, four
glioblastoma patients and three acute myeloid leukaemia (AML) patients have
started treatment with dendritic cells so far. The new generation of
dendritic cells characterized by superior in-vitro functionality when
compared to commonly used dendritic cells could be produced from cells of all
patients, regardless of the type of malignancy. The included patients
suffering from solid tumours clearly showed a longer progression free
survival than could be expected according to the stage of their disease,
except for the patient with prostate cancer, who due to personal reasons
prematurely dropped out of the program. The three AML patients which were
included in this dendritic cell compassionate use program have been showing a
promising course of disease, however these cases are still too early for
evaluation.

Conclusion of this evaluation by Prof. Gunnar Kvalheim,
Head of Department of Cellular Therapy, Oslo University Hospital
: "Solid tumour patients suffering from advanced disease treated with these DC
vaccines have a prolonged progression free survival, showing that this
immunotherapeutic approach will be a promising alternative to current
standard therapies."

More detailed information can be found in the abstract under the following
link:http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3682&sKey=eae2...

The Oslo University Hospital has an agreement with Medigene for use of
Medigene`s new generation DC vaccines for their ongoing academic clinical
studies.

Prof. Dolores J. Schendel, Chief Scientific Officer of Medigene AG
: "These positive results encourage us in pursuing our DC vaccine development
program for which we have recently started our own clinical AML trial,
complementing the ongoing academic clinical studies."

About Medigene's DC vaccines:
The platform for the development of new generation antigen-tailored DC
vaccines is the most advanced platform of the three highly innovative and
complementary immunotherapy platforms of Medigene Immunotherapies. The DC
vaccines are currently being evaluated in a company-sponsored clinical trial
in acute myeloid leukaemia (AML) as well as in two ongoing clinical
investigator-initiated trials: a clinical phase I/II trial in AML at the
Ludwig-Maximilian University Hospital Großhadern, Munich, and a clinical
phase II trial in prostate cancer at the Oslo University Hospital. Moreover,
a compassionate use program is being conducted at the Department of Cellular
Therapy at the Oslo University Hospital.

Medigene's dendritic cell product platform allows the design of new generation
dendritic cell vaccines. Dendritic cells can take up antigens efficiently,
process them and present them on their surface in a form that can induce
antigen-specific T cells to proliferate and mature. This way T cells can
recognize and eliminate antigen-bearing tumour cells. Dendritic cells can
also induce natural killer cells (NK cells) to become active and attack
tumour cells. Scientists of Medigene Immunotherapies have developed new, fast
and efficient methods for preparing autologous (patient-specific) mature
dendritic cells which have relevant characteristics to activate both T cells
and NK cells. The dendritic cells can be loaded with various tumour antigens
to treat different types of cancer and are designed for treatment of minimal
residual disease or use in combination therapies.

Further audio-visual education about Medigene's DCs
at:https://vimeo.com/123005832

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. Medigene concentrates on
the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed
to partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visitwww.medigene.com.

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene®is a registered trademark of Medigene
AG. Medigene ImmunotherapiesTMis a registered trademark of Medigene
Immunotherapies GmbH. Trianta ImmunotherapiesTMis a registered trademark of
Medigene Immunotherapies GmbH. These trademarks may be owned or licensed in
select locations only.

Contact Medigene

Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please
visit:http://www.medigene.de/unsubscribe
---------------------------------------[1]Compassionate Use: Prescription of as-yet unapproved drugs in particularly
severe cases where there are no treatment alternatives

Press release as PDF
http://hugin.info/132073/R/1912602/682709.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#1912602

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.